{
  "docId": "019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "docSlug": "7d5a5b546ee496a809a6ede1a6c2c260",
  "documentTitle": "Equillium | Investor Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 32,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes before/after patient photos and comparative data against Mogamulizumab.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7b67-762e-8b55-8f35aa9a2cc0/20",
  "deckHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "deckJsonHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0.json",
  "deckAnchorHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.92,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "callout",
      "text": "Favorable safety and tolerability demonstrated in 93 subjects across populations with compelling clinical activity observed in CTCL patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9578395b-d654-4fe8-b443-499fcfd39c87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.51,
        "x": 0.46,
        "y": 0.64
      },
      "kind": "image",
      "text": "Before and after patient photos showing skin improvement at Week 1 vs Week 16",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2847cf26-aab9-4ab1-a7ab-11ffa5c79c24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.42,
        "x": 0.04,
        "y": 0.33
      },
      "kind": "list",
      "text": "Phase 1/2 MAD study in Cutaneous T Cell Lymphoma (n=30)\nHeavily pre-treated, refractory patient population (median of 5 prior systemic treatments)\nDose escalation (0.5, 1, 2, 4mg/kg) with 4-week treatment/assessment period (n=30) followed by 12+ week extension (n=19)\nNo drug related SAEs, no DLTs and no clinically significant laboratory abnormalities\nDose-dependent PK/PD correlated with improved skin scores (mSWAT)\n2mg/kg was selected dose for study expansion and extension",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "940916df-494f-4aef-b697-80da0124be38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.12,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1) Kim et al., Lancet Oncol., 2018. 2) Querfeld et al., Blood, 2019. mSWAT = modified severity-weighted assessment CTCL = Cutaneous T cell Lymphoma",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "199c6352-0321-49ae-9ea7-5db1cc697b50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.51,
        "x": 0.46,
        "y": 0.345
      },
      "kind": "table",
      "text": "Response Rate in Stage IB/II Patients\nMAVORIC Phase 3 Trial | EQ101 Phase 1/2\nMogamulizumab (n=68) | EQ101 (n=19)\n27.9% | 42.1%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1536c2f-84dc-429a-ac27-dc9bb2065cae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.87,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "EQ101: Clinically Validated in Severe Dermatological Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea551be8-0588-4214-85cb-ecbc80c9e356",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "821033f7-cf44-4413-b894-ecb6a092d5cb",
      "evidence": "list/bullet: Phase 1/2 MAD study in Cutaneous T Cell Lymphoma (n=30) Heavily pre-treated, refractory patient population (median of 5 prior systemic treatments)",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "dfe673d8-7eb5-4d5b-a9a4-1efc0fc206aa",
      "evidence": "Direct comparison of response rates between MAVORIC trial and EQ101 trial",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 23,
      "from": 5,
      "beatId": "ad87164c-eefb-4286-988c-3da24e7ea3ff",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 5-23 present Equillium's platform and pipeline as a solution to the problems identified, providing relief for patients with immunological disorders.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}